The New Haven, Conn.-based drugmaker will also relocate its headquarters to Boston, maintaining its New Haven plant as a research center of excellence.
It expects to deliver about $270 million in pre-tax, adjusted savings each year by 2019, which will allow it to prioritize growth opportunities, particularly in regards to its rare disease business.
The drugmaker was recently investigated on allegations related to sales practices for one of its drugs, Soliris, after which members of its senior management team resigned, reports CNBC.
More articles on supply chain:
FDA calls out EpiPen manufacturer for product flaws linked to patient deaths
Facebook promotes ‘clinical trials strategy’ to drugmakers
CMS to replace beneficiary-owned medical equipment damaged by Harvey
